Celator(R) Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
June 24, 2015Celator Pharmaceuticals announces positive induction response results from Phase 3 study of CPX-351 in patients with high-risk (secondary) acute myeloid leukemia. Data on overall survival, the primary endpoint, are expected in the first quarter of 2016.
More »
Glaukos Corporation Announces Pricing of Its Initial Public Offering
June 24, 2015Glaukos Corporation announces the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $18.00 per share and will be traded under the symbol “GKOS.”
More »
CLOVIS ONCOLOGY APPOINTS DR. LINDSEY ROLFE AS CHIEF MEDICAL OFFICER
June 22, 2015Clovis Oncology appoints Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, as Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance, to become effective in early August.
More »